The funding round was led by Montage Ventures, with participation from Continuum Health Ventures and existing backers like Laidlaw Ventures and APEX Ventures. Notable individual investors included Dr Maximilien Levesque, CEO and co-founder of Aqemia, and Naheed Kurji, former President of Recursion and founder of Cyclica. Additionally, Dr Joseph Lehár, former SVP of R&D Strategy at Owkin, has joined CardiaTec’s scientific advisory board.

Cardiovascular disease remains the leading global cause of death, claiming 17.9 million lives each year. Despite its significant impact, innovation in this therapeutic area has stagnated due to an incomplete understanding of the underlying biology. This knowledge gap has hindered the success of costly clinical trials, resulting in diminished investment and a lack of new treatment options, leaving an urgent need for more effective therapies.

CardiaTec seeks to address this by leveraging computational approaches to unlock new drug targets. The company utilises multi-omics data – comprising information from the genome, proteome, epigenome, and transcriptome – to gain deeper insights into the complex biology of cardiovascular disease. By analysing vast datasets that are beyond human capability, CardiaTec aims to discover more precise and targeted treatments.

To support its research, CardiaTec has built a network of 65 hospitals across the US and UK, facilitating the collection of human heart samples for data generation. The company is in the process of creating the largest multi-omics dataset of human heart tissue, positioning itself as a leader in the development of next-generation cardiovascular therapeutics.

Raphael Peralta, CEO and co-founder of CardiaTec, commented: "Modelling complex cardiovascular disease biology across multiple omic dimensions has immense potential in unlocking new therapeutic strategies that will challenge the current standard of care. Over the last several years, I am proud of the team's relentless drive to reach important milestones and our collective ambition to tackle a tough global problem. I look forward to working with our investors to accelerate our development."

Todd Kimmel, Partner at Montage Ventures, stated: “CardiaTec' is at the forefront of a new era in cardiovascular drug discovery. Their unique combination of the world's largest multi-omics dataset from human cardiac tissues and advanced computational technology positions them to uncover novel drug targets for the world's leading cause of death. With strong pharma industry connections, a growing market need, and a proprietary data moat, CardiaTec has the potential to revolutionise how we approach and treat cardiovascular diseases.”

CardiaTec is a spin-out from the Han Lab at the University of Cambridge, founded in 2021 by Prof Namshik Han (CTO) and two alumni, Raphael Peralta (CEO) and Thelma Zablocki (COO), who have been awarded Forbes 30 under 30 Europe.

Drawing on research conducted over the last decade, the company has brought together industry experts from leading organisations, including Bristol Myers Squibb, Cleveland Clinic, and Recursion Pharmaceuticals.